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Objective. Arthritis is one of the hallmarks of
late-stage Lyme disease. Previous studies have shown
that infection with Borrelia burgdorferi, the causative
agent of Lyme disease, results in degradation of proteo-
glycans and collagen in cartilage. B burgdorferi do not
appear to produce any exported proteases capable of
digesting proteoglycans and collagen, but instead, in-
duce and activate host proteases, such as matrix metal-
loproteinases (MMPs), which results in cartilage degra-
dation. The role of aggrecanases in Lyme arthritis has
not yet been determined. We therefore sought to delin-
eate the contribution of aggrecanases to joint destruc-
tion in Lyme arthritis.
Methods. We examined the expression patterns of
aggrecanases 1 and 2 (ADAMTS 4 and 5, respectively)
in B burgdorferi–infected primary human chondrocyte
cell cultures, in synovial fluid samples from patients
with active Lyme arthritis, and in the joints of mice by
real-time quantitative reverse transcription–polymerase
chain reaction and immunoblotting techniques. Bovine
cartilage explants were used to determine the role of
aggrecanases in B burgdorferi–induced cartilage degra-
dation.
Results. ADAMTS-4, but not ADAMTS-5, was
induced in human chondrocytes infected with B burg-
dorferi. The active forms of ADAMTS-4 were increased
in synovial fluid samples from patients with active Lyme
arthritis and were elevated in the joints of mice infected
with B burgdorferi. Using cartilage explant models of
Lyme arthritis, it appeared that the cleavage of aggre-
can was predominantly mediated by “aggrecanases”
rather than MMPs.
Conclusion. The induction of ADAMTS-4 by B
burgdorferi results in the cleavage of aggrecan, which
may be an important first step that leads to permanent
degradation of cartilage.
Oligoarticular arthritis is a prominent feature of
late-stage Lyme disease in North America (1). When left
untreated, infection with Borrelia burgdorferi, the caus-
ative agent of Lyme disease, can result in intermittent or
chronic arthritis that may progress to an erosive arthritis
with certain histopathologic similarities to rheumatoid
arthritis (RA) (2). The progression of erosions in Lyme
arthritis is quite delayed in comparison with the septic
arthritis caused by other bacterial agents. This may be
due to the fact that cartilage degradation in response to
B burgdorferi occurs as a result of induction of host
proteases rather than bacterial proteases (3). Elevations
in the levels of host matrix metalloproteinases (MMPs)
have been found in the synovial fluid (SF) of patients
with Lyme arthritis, and B burgdorferi has been shown to
induce specific MMPs from chondrocytes (4). Inhibitors
of MMPs have been shown to decrease B burgdorferi–
induced cartilage degradation (3).
Articular cartilage consists of an extracellular
matrix that is synthesized and maintained by chondro-
cytes, the resident cells of the tissue. Aggrecan, which
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consists of a protein core backbone substituted with
many highly sulfated glycosaminoglycans (GAGs), is the
major proteoglycan present within articular cartilage (5).
The high negative-charge density of the GAG chains
present on aggrecan provides cartilage with the ability to
resist mechanical compression. In arthritic diseases char-
acterized by cartilage destruction, aggrecan is one of the
first matrix components to be degraded. While many
enzymes have been demonstrated to be capable of
cleaving the protein backbone of aggrecan, the predom-
inant activity responsible for the degradation of aggre-
can in cartilage is aggrecanase (6–11). Five sites along
the aggrecan core have been shown to be susceptible to
aggrecanase cleavage. These are located within the
interglobular domain of the core protein between amino
acid residues TEGE373 and 374ARGS, and within the
chondroitin sulfate attachment region between amino
acids GELE1480 and 1481GRGT, KEEE1666 and
1667GLGS, TAQE1771 and 1772AGEG, and VSQE1871
and 1872LGQR (7–9,12).
Although MMPs may be involved in the cleavage
and release of aggrecan from the cartilage matrix,
studies in other diseases, including RA, osteoarthritis
(OA), and after joint injury, have shown that the major-
ity of aggrecan fragments found in SF are generated by
aggrecanases, which cleave aggrecan at sites different
from those used by MMPs (13–16). ADAMTS-4 (aggre-
canase 1) and ADAMTS-5 (aggrecanase 2) have been
identified as the known enzymes that are most efficiently
capable of cleaving aggrecan (17). ADAMTS-4 and
ADAMTS-5 are members of the family of proteins
known as a disintegrin and metalloproteinase with
thrombospondin motifs. Aggrecanase-like activity in SF
from patients with Lyme arthritis has previously been
reported (3). However, the induction of aggrecanases
and the relative contributions of aggrecanases and
MMPs in B burgdorferi–induced cartilage destruction
have not previously been reported.
In the present study, we examined the role of
ADAMTS-4 and ADAMTS-5 in cartilage degradation
following B burgdorferi infection in patients with Lyme
disease, as well as in both in vitro and in vivo models of
Lyme disease.
MATERIALS AND METHODS
Primary cell cultures and infection with B burgdorferi.
Primary human chondrocytes derived from a healthy donor
were purchased from Cambrex (Walkersville, MD) and main-
tained in chondrocyte growth medium (Cambrex). Primary
human dermal fibroblasts and primary human pulmonary
artery smooth muscle cells were purchased from Cell Appli-
cations (San Diego, CA). Cell cultures were maintained and
infected as previously described (18). For inhibitor experi-
ments, various inhibitors of MAPK and JAK/STAT pathways
were added to the cells in fresh serum-free medium 2 hours
prior to infection with B burgdorferi and then harvested at 24
hours after infection. The inhibitor concentrations we used (20
M SP600125, 3 M SB203580, 10 M U0126, and 30 g/ml of
a JAK-3 inhibitor I [JAK-3I]) were selected on the basis of
previous dose-finding studies, both by our group and by others,
showing no visible cytotoxic effect on the human chondrocyte,
as judged by trypan blue exclusion (19). Cells were washed and
harvested in cold phosphate buffered saline, and the cell
pellets were stored at –70°C until used.
Real-time quantitative reverse transcription–
polymerase chain reaction (RT-PCR). Total RNA was purified
from human chondrocytes with TRIzol (Invitrogen, San Diego,
CA) according to the manufacturer’s instructions. First-strand
synthesis of complementary DNA (cDNA) from total RNA
was performed using ImProm II reverse transcriptase (Pro-
mega, Madison, WI) according to the manufacturer’s instruc-
tions. Control reactions performed in the absence of reverse
transcriptase were used to check for contamination with
genomic DNA. The cDNA samples that had been contami-
nated by genomic DNA were discarded, and the original RNA
was treated with DNase before the reverse transcriptase
reaction was repeated. Quantitation of cDNA from specific
messenger RNA (mRNA) transcripts was accomplished by
real-time quantitative RT-PCR (iCycler; Bio-Rad, Hercules,
CA) using SYBR Green technology (QuantiTect SYBR Green
PCR kit; Qiagen, Valencia, CA) as previously described (18).
The following primers were used for PCR amplifica-
tion: for human ADAMTS-4, 5-CACGCTGGGTATGGCT-
GATG-3 (forward) and 5-CATGACATGGCGAGAGG-
TGC-3 (reverse); for mouse ADAMTS-4, 5-CCCGAG-
TCCCATTTCCCGCA-3 (forward) and 5-GGGTCTG-
GGCGGCACTTGGC-3 (reverse); for bovine ADAMTS-4, 5-
GCCTTCAAGCACCCGAGCAT-3 (forward) and 5-
CATCCTCCACAATGGCGCAG-3 (reverse); for bovine
ADAMTS-5, 5-TGTCCGAGGACGGTGTGTGA-3 (forward)
and 5-CAGGGCTAAGTAGGCAGGGAATC-3 (reverse);
and for bovine GAPDH, 5-CATGTTTGTGATGGG-
CGTGA-3 (forward) and 5-GCGCCAGTAGAAGCAG-
GGAT-3 (reverse). The human -actin and mouse nidogen
primer sequences we used have been described elsewhere (18,20).
All of the primers we used were validated for amplification
efficiency according to the method of Livak and Schmittgen (21),
and the absolute value of the slope of the log template amount
versus the difference in threshold cycle (Ct) for each primer
combination was 0.1. Calculations of expression were normal-
ized to -actin (human) or nidogen (mouse) using the Ct
method, where the amount of target, normalized to an endoge-
nous reference and relative to a calibrator, is given by 2–Ct,
where Ct is the cycle number of the detection threshold.
Immunoblot analysis. After incubation with B burgdor-
feri, total cellular protein extracts were prepared from chon-
drocyte cultures as described previously (18,19). Equal
amounts of protein were separated by 10% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and transferred to a
polyvinylidene difluoride (PVDF) membrane. Immunoblotting
was performed with polyclonal antibodies to human
ADAMTS-4 (1:500 dilution; Santa Cruz Biotechnology, Santa
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Cruz, CA) and horseradish peroxidase–conjugated anti-goat
secondary antibody (1:1,000 dilution; Southern Biotechnology,
Birmingham, AL).
Patients. SF was obtained from 9 patients with un-
treated Lyme arthritis and 9 patients with persistent Lyme
arthritis after antibiotic therapy. The samples used have been
previously described (4,18,22). Use of the patient samples was
reviewed and approved by the Institutional Review Board of
the Tufts–New England Medical Center. All patients were
infected when they were in the northeastern US. All had
oligoarticular arthritis involving one or both knees. All patients
in both groups met the Centers for Disease Control and
Prevention (CDC) clinical criteria for the diagnosis of Lyme
disease (23). Patients had mono- or oligoarticular arthritis
affecting at least 1 knee, accompanied by positive findings on
a serum IgG Western blot test for Lyme disease, as interpreted
according to the CDC/Association of State and Territorial
Public Health Laboratory Directors criteria (24). SF samples
from all 18 patients with untreated Lyme arthritis tested
positive for B burgdorferi DNA by PCR, performed as de-
scribed by Nocton et al (25). All SF samples from patients with
persistent Lyme arthritis tested negative for B burgdorferi DNA
by PCR.
The mean duration of symptoms at the time of sample
collection was 2.2 years in the untreated group (range 6 months
to 6 years) and 1.7 years in the posttreatment group (range 3
months to 6 years). All patients in the posttreatment group
received at least 4 weeks of treatment with an antibiotic that is
active against B burgdorferi (median number of courses of
antibiotic was 2). Samples were obtained a minimum of 2
months after patients had completed their antibiotic courses.
All specimens were divided into aliquots and stored at
–70°C until used. An equal volume of each sample (1 l) was
used for immunoblotting. All blots were normalized to stan-
dards, which were included in every blot to allow comparison
between blots.
SF samples from patients with other arthritic diseases
(13 with RA, 12 with OA, 4 with gouty arthritis, and 2 with
reactive postinfectious arthritis [ReA]) were collected from
discarded specimens obtained during the course of standard
patient care. All SF was obtained during active disease from an
involved knee joint.
Mice and infection with B burgdorferi. C3H/HeN,
C57BL/6, and BALB/c mice were purchased from Charles
River (Wilmington, MA) and from Taconic (Hudson, NY).
The procedures used were reviewed and approved by the
Institutional Animal Care and Use Committee of Tufts Uni-
versity. Five-day-old mice were infected intradermally by nee-
dle inoculation with B burgdorferi strain N40 (104 low-passage
infectious organisms per mouse) or were sham infected. Mice
were killed 2 weeks postinfection, at which time the B
burgdorferi–infected mice were clearly distinguishable from the
sham-infected mice by the visible swelling of the ankle joints.
Cartilage was microdissected from the ankle joints by using a
stereomicroscope to separate the cartilage from bone and
adjoining synovial tissue (18), and total RNA was isolated
using TRIzol. Successful infection of individual mice was
confirmed by culturing ear samples in BSK-H medium and
monitoring the growth of B burgdorferi by darkfield micros-
copy.
Preparation of bovine cartilage explants and infection
with B burgdorferi. Bovine cartilage explants were prepared
and maintained as previously described (26). Low-passage
infectious B burgdorferi strain N40 organisms (107) were
washed 3 times in culture medium and added to wells, each of
which contained a single 3-mm explant. Batimastat (250 nM)
(BB-94; British Biotech, Oxford, UK) or BAY 12-9566 (300
nM; Bayer Pharmaceuticals, Elkhart, IN) was added at the
same time as the B burgdorferi in a final volume of 200 l of
culture medium. The culture supernatant was collected after
48 hours and stored at –70°C until used.
To detect BC-3–immunoreactive fragments, culture
supernatants from bovine cartilage explants were transferred
to a PVDF membrane and detected with mouse monoclonal
BC-3 antibody (1:100 dilution; Abcam, Cambridge, MA) and
alkaline phosphatase–conjugated anti-mouse secondary anti-
body (1:10,000 dilution; Promega).
Measurement of sulfated GAGs. Quantitation of sul-
fated GAGs was performed using the dimethylmethylene blue
(DMMB) method (27). Briefly, culture supernatants (3–10 l)
from bovine cartilage explants were mixed with 1 ml of DMMB
solution (38.45 M 1,9-dimethylmethylene blue, 40.49 mM
glycine, 40.55 mM NaCl, and 95 ml of 0.1M HCl, pH 3.0).
Optical density was measured at 525 nm within 30 minutes and
was compared with the optical density of known concentra-
tions of chondroitin sulfate A as a standard.
Statistical analysis. Each experiment was performed
2–4 times, as indicated. Statistical significance was analyzed
using the nonparametric Mann-Whitney U test in the SPSS
software package (SPSS, Chicago, IL). P values less than 0.05
were considered significant.
RESULTS
B burgdorferi–induced expression of ADAMTS-4
in primary human chondrocytes. We first examined the
expression pattern of aggrecanases in primary human
chondrocytes following B burgdorferi infection. Cultures
of human chondrocytes in serum-free medium were
infected with B burgdorferi at various multiplicities of
infection (MOI; the number of bacteria per cell) or were
sham infected and harvested 24 hours later. The cDNA
was synthesized using the total cellular RNA from
these cells, and the expression of ADAMTS-4 and
ADAMTS-5 was examined by real-time quantitative
RT-PCR (Figure 1A). We found that ADAMTS-4
mRNA was induced in a dose-dependent manner fol-
lowing B burgdorferi infection. Expression of
ADAMTS-4 was significantly increased in treated cells
as compared with untreated cells (63-fold at an MOI of
1 and 1,000-fold at an MOI of 100; P  0.05). An MOI
of 10 was used in all subsequent experiments in this
study.
The change in expression of ADAMTS-4 was
seen in as little as 0.5 hours after addition of B burgdor-
feri and remained high through 72 hours after infection
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(Figure 1B). There was no change in the expression of
ADAMTS-5 in infected human chondrocytes, as deter-
mined by real-time quantitative RT-PCR (data not
shown).
To determine if the changes in gene transcription
also paralleled increases in ADAMTS-4 protein expres-
sion, whole cell extracts of human chondrocytes, either
sham infected or infected with B burgdorferi for different
time periods, were analyzed by immunoblotting using
an antibody raised against human ADAMTS-4.
ADAMTS-4 is produced as a proenzyme that requires
intracellular furin-mediated removal of the N-terminal
pro domain (28), resulting in generation of the p68 form.
While the p68 form can degrade the C-terminal chon-
Figure 1. Borrelia burgdorferi–induced expression of ADAMTS-4 in primary human chondrocytes. A, Human
chondrocytes were infected with B burgdorferi at various multiplicities of infection (MOI), and expression of
ADAMTS-4 was examined by real-time quantitative reverse transcription–polymerase chain reaction (RT-PCR)
analysis at 24 hours postinfection. Expression of ADAMTS-4 was normalized to that of -actin and the relative
expression is shown. The time course of ADAMTS-4 induction in response to infection with B burgdorferi (10 MOI)
was measured by B, real-time quantitative RT-PCR and C, Western blotting (top). The active p53-kd band of
ADAMTS-4 at each time point was densitometrically scanned, and the relative intensity of each band was normalized
to the loading control, STAT-6 (bottom). Results are representative of 3–5 real-time quantitative RT-PCR
experiments and 2 Western blot experiments. Values are the mean  SD.   P  0.05 versus chondrocytes not
infected with B burgdorferi, by nonparametric Mann-Whitney U test.
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droitin sulfate–bearing region, further C-terminal trun-
cation of ADAMTS-4 is required for destructive cleav-
age of aggrecan in the interglobular domain. This
truncation occurs through the activity of membrane type
4 MMP, resulting in the p53 and p40 forms of the
proteinase. The p53 form acts as the major aggrecanase
(29).
There was a basal level of ADAMTS-4 protein
expression in primary human chondrocytes, which in-
creased within 48 hours following the addition of B
burgdorferi and continued to increase up to 72 hours
after infection (Figure 1C). Both the p53 and p40 forms,
representing activated ADAMTS-4, were found in these
cells. Although the transcript levels of ADAMTS-4
peaked at 24 hours after infection, protein levels contin-
ued to increase through the later time points, as mea-
sured by densitometry (Figures 1B and C). The induc-
tion of ADAMTS-4 was due to the addition of B
burgdorferi, since uninfected samples collected at match-
ing time points did not show induction of ADAMTS-4
(data not shown).
Cell-type specificity of ADAMTS-4 induction fol-
lowing B burgdorferi infection. To determine the speci-
ficity of ADAMTS-4 induction in human chondrocytes
following B burgdorferi infection, we infected primary
human dermal fibroblast cultures, which may contact B
burgdorferi during the initial entry into humans, and
primary human pulmonary artery smooth muscle cell
cultures, which are found in an area where no pathology
has been reported in Lyme disease. There was no
induction of ADAMTS-4 from either cell type, as deter-
mined by real-time quantitative RT-PCR (data not
shown).
Expression of ADAMTS-4 in SF samples from
patients with treated and untreated Lyme arthritis. In
order to determine the presence of ADAMTS-4 in the
SF of patients with Lyme arthritis, SF samples from 9
patients with untreated Lyme arthritis were examined by
Figure 2. Expression of ADAMTS-4 in synovial fluid (SF) from patients with different forms of arthritis.
A, SF samples from 9 patients with persistent Lyme arthritis after antibiotic treatment (PLA) and from 9
patients with untreated Lyme arthritis (ULA) were examined for the presence of ADAMTS-4 by Western
blotting. Equal volumes of SF (1 l) were subjected to sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and immunoblotted with an anti–ADAMTS-4 antibody. B, SF samples from 13 patients
with rheumatoid arthritis (RA), 12 with osteoarthritis (OA), 4 with gouty arthritis (GA), and 2 with
reactive postinfectious arthritis (ReA) were similarly analyzed for the expression of ADAMTS-4 by
immunoblotting. The active p53-kd form of ADAMTS-4 was densitometrically scanned in a randomly
selected subset of samples and normalized to a comparator sample (1 SF sample from a patient with
persistent Lyme arthritis after antibiotic treatment) that was run on each gel (the value of which was
arbitrarily set at 1), and the relative expression of ADAMTS-4 in each arthritis group was plotted. Bars
show the mean. P values were determined by nonparametric Mann-Whitney U test.
AGGRECANASE 1 IN LYME ARTHRITIS 3323
immunoblotting. Because normal SF is difficult to obtain
in amounts sufficient for testing, we used for comparison
SF samples from 9 patients with persistent Lyme arthri-
tis after antibiotic therapy in whom no SF B burgdorferi
was detectable, as well as SF samples from 13 patients
with RA, 12 with OA, 4 with gouty arthritis, and 2 with
ReA. The ADAMTS-4–specific band was detected in all
patients. The level of expression of activated
ADAMTS-4 (p53) was significantly higher (P  0.0207)
in patients with untreated Lyme arthritis than in those
with persistent Lyme arthritis after antibiotic therapy
(Figures 2A and B). SF levels of ADAMTS-4 were also
elevated in RA (P  0.0125) and OA (P  0.0492)
patients as compared with patients with persistent Lyme
arthritis after antibiotic therapy and were similar to
those in patients with untreated Lyme arthritis (Figure
2B). Expression of ADAMTS-4 in SF samples from
patients with untreated Lyme arthritis (P  0.004), RA
(P  0.0039), and OA (P  0.0092) were also signifi-
cantly higher than those in SF samples from patients
with gouty arthritis. Expression of ADAMTS-4 in SF
from patients with ReA was also lower and was similar
to that in patients with persistent Lyme arthritis after
antibiotic therapy, but because of the sample size (n 
2), statistical analysis was not done.
Induction of ADAMTS-4 in murine cartilage.
Mice have been an invaluable model in the study of
Lyme disease pathogenesis. Mice develop ankle and
knee swelling that is clinically similar to that seen in
humans with Lyme disease. Different strains of mice
show variable degrees of arthritis in response to infec-
tion with B burgdorferi. In order to determine if
ADAMTS-4 expression may play a role in the develop-
ment of arthritis in a murine model of Lyme disease, we
used real-time quantitative RT-PCR to evaluate the
expression of ADAMTS-4 and ADAMTS-5 in the joints
of C3H/HeN mice, a strain that is highly susceptible to
arthritis. Expression of ADAMTS-4 was significantly
increased 4.2-fold (P  0.0001) in cartilage from B
burgdorferi–infected mice as compared with cartilage
from sham-infected mice (Figure 3A). There was a
single outlier showing very high induction of
ADAMTS-4 in the B burgdorferi–infected group; how-
ever, when the data for that animal were removed from
the analysis, the expression of ADAMTS-4 remained
statistically significant (P  0.0002). There was minimal
Figure 3. Induction of ADAMTS-4 and ADAMTS-5 in murine cartilage by Borrelia burgdorferi. Five-day-old C3H/HeN,
BALB/c, and C57BL/6 mice were infected with B burgdorferi (Bb; 104 low-passage infectious organisms per mouse) or were
sham infected. Mice were killed 2 weeks postinfection, ankle joint cartilage was microdissected, and total RNA was isolated.
The cDNA generated from total RNA was analyzed for ADAMTS-4 or ADAMTS-5 expression by real-time quantitative
reverse transcription–polymerase chain reaction analysis. The expression of ADAMTS-4 or ADAMTS-5 was normalized to that
of nidogen, and the relative expression is shown. Bars show the median. P values were determined by nonparametric
Mann-Whitney U test. A, Expression of ADAMTS-4 in C3H/HeN (n  10), BALB/c (n  6), and C57BL/6 (n  5) mice. B,
Expression of ADAMTS-5 in C3H/HeN mice (n  5 sham-infected mice; n  6 B burgdorferi–infected mice).
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increase (1.7-fold) in the expression of ADAMTS-5
between infected and sham-infected groups, although
the difference did reach statistical significance (P 
0.035). The biologic significance of this finding is not
clear (Figure 3B).
In order to examine whether the difference in the
severity of Lyme arthritis observed in different strains of
mice could be correlated with the level of ADAMTS-4,
we compared the expression of ADAMTS-4 in 2 well-
characterized strains of mice that are less susceptible to
arthritis, BALB/c and C57BL/6, with the expression in
the C3H/HeN mice. None of the BALB/c mice showed
any observable swelling of any joint as compared with
the sham-infected mice. There was mild, but noticeable,
swelling on both rear tibiotarsal joints in B burgdorferi–
infected C57BL/6 mice, but the swelling was much less
than that observed in C3H/HeN mice. No significant
increase in the expression of ADAMTS-4 in the cartilage
of either BALB/c or C57BL/6 mice was seen by real-time
quantitative RT-PCR (Figure 3A).
Mechanism of B burgdorferi–induced ADAMTS-4
gene expression. We have previously shown that B
burgdorferi induces activation of the MAPK and JAK/
STAT pathways in human chondrocytes (19). To examine
the role of these pathways in the induction of ADAMTS-
4, we determined the expression of ADAMTS-4 in the
presence of pathway-specific inhibitors. Inhibitors of
ERK-1/2 (U0126) and JNK (SP600125) inhibited gene
transcription of ADAMTS-4 by 81% (P  0.037) and
80% (P  0.037), respectively, as compared with the B
burgdorferi–infected sample alone (Figure 4). However,
inhibition of p38 MAPK with SB203580 had no effect on
the expression of ADAMTS-4 following B burgdorferi
infection. Inhibition of the JAK/STAT pathway by
JAK-3I completely inhibited (100%) (P  0.01) the
expression of ADAMTS-4 (Figure 4).
Role of ADAMTS-4 in B burgdorferi–induced
cartilage degradation. We next used a bovine articular
cartilage explant model to determine the contribution of
aggrecanases (including ADAMTS-4) in the degrada-
tion of the cartilage matrix following B burgdorferi
infection. Bovine cartilage has been previously shown to
produce MMPs in response to B burgdorferi in a manner
consistent with that seen in human chondrocytes and
identical to that seen in monkey cartilage. Although the
use of human cartilage would be preferable, it is com-
plicated because of the difficulty in obtaining sufficient
and appropriate samples for study. The inability to select
identically located cartilage tissue from different human
subjects could lead to significant experimental variation,
since chondrocytes found in different types of cartilage
and at different levels of cartilage differ significantly in
their responses to stimuli. The bovine cartilage explants
that were used were taken from identical locations in the
knee joint, and this model has been widely used by other
investigators in examinations of cartilage degradation
(3,16,26,30).
We first confirmed that infection of bovine car-
tilage explants with B burgdorferi induced the expression
of ADAMTS-4 (Figure 5A); expression was increased
57-fold as compared with that in uninfected explants (P
 0.0286). We next evaluated the role of ADAMTS-4 in
cartilage degradation using different inhibitors of MMPs
and ADAMTS. Batimastat (BB-94) is a hydroxamate
inhibitor, which binds the zinc atom at the active site of
the enzyme. It inhibits both MMPs and ADAMTS
proteinases. As previously reported (3), the addition of
Figure 4. Role of p38 MAPK, ERK-1/2, JNK, and JAK/STATs in
Borrelia burgdorferi–induced expression of ADAMTS-4 in primary
human chondrocytes. Primary human chondrocyte cultures were
treated with p38 MAPK inhibitor (SB203580), JNK inhibitor
(SP600125), ERK-1/2 inhibitor (U0126), or JAK/STAT pathway inhib-
itor (JAK-3I) for 2 hours, and subsequently infected with B burgdorferi
(Bb; 10:1 multiplicity of infection [Bb to cells]) or were sham infected.
Cells were harvested at 24 hours postinfection, and ADAMTS-4
expression was examined by real-time quantitative reverse
transcription–polymerase chain reaction analysis. The expression of
ADAMTS-4 was normalized to that of -actin. The expression of
ADAMTS-4 in cells stimulated with B burgdorferi alone was arbitrarily
set at 1, and the relative expression is shown. Values are the mean and
SD of 3 experiments.   P  0.05;   P  0.01 versus B
burgdorferi–infected chondrocytes, by nonparametric Mann-Whitney
U test.
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BB-94 significantly inhibited B burgdorferi–induced
GAG release (P  0.046) (Figure 5B).
GAGs, including aggrecan, can be released from
the cartilage matrix after cleavage with either MMPs or
“aggrecanases” such as ADAMTS-4. The cleavage site
recognized by MMPs differs from that recognized by
aggrecanases, resulting in the generation of neoepitopes
that can be distinguished by specific antibodies. Using an
antibody raised against the neoepitope generated from
aggrecan by cleavage with aggrecanases (BC-3 anti-
body), we found that BB-94 also significantly inhibited
the generation of this neoepitope. We did not have
access to a specific inhibitor of ADAMTS-4, so in order
to determine whether the release of GAGs was due
predominantly to cleavage by MMP-type enzymes or by
ADAMTS-type enzymes, we compared the effects of
BB-94 with that of a more specific MMP inhibitor, BAY
12-9566. BAY 12-9566 is a selective nonpeptide biphenyl
inhibitor of MMPs with nanomolar inhibitory activity
against MMP-2, MMP-3, and MMP-9 (31,32), but no
known ability to inhibit aggrecanase activity. As ex-
pected, using the BC-3 antibody, we found that BAY
12-9566 did not inhibit the amount of aggrecanase-
cleaved aggrecan detected in supernatants after B burg-
dorferi infection, suggesting that it did not have an effect
on ADAMTS activity (Figure 5C). Total GAG release in
the presence of B burgdorferi was also not reduced by
BAY 12-9566 (Figure 5B). This strongly suggests that
Figure 5. Role of ADAMTS-4 in Borrelia burgdorferi–induced cartilage degradation. A, Bovine cartilage
explants (n  4) were infected with B burgdorferi (Bb; 10:1 multiplicity of infection [Bb to cells]) or were sham
infected for 2 days, and the expression of ADAMTS-4 was examined by real-time quantitative reverse
transcription–polymerase chain reaction analysis. The expression of ADAMTS-4 was normalized to that of
bovine GAPDH, and the relative expression is shown. Bars show the mean. The P value was determined by
nonparametric Mann-Whitney U test. B, Bovine cartilage explants were infected with B burgdorferi alone or
in the presence of 250 nM batimastat BB-94 (an inhibitor of both matrix metalloproteinases [MMPs] and
ADAMTS proteinases) or 300 nM BAY 12-9566 (a selective inhibitor of MMPs), or were sham infected, and
the supernatants were collected 48 hours postinfection. Levels of glycosaminoglycans (GAGs) in the
supernatants were measured by the dimethylmethylene blue method. Values are the mean and SD of 3
experiments, each performed in triplicate.   P  0.05 versus B burgdorferi–infected explants, by
nonparametric Mann-Whitney U test. C, Culture supernatants from the bovine cartilage explants were
subjected to electrophoresis on sodium dodecyl sulfate–polyacrylamide gels, and the aggrecanase breakdown
fragments were detected using the BC-3 monoclonal antibody. Arrows indicate the aggrecanase-specific
fragments, which typically run between 50 kd and 250 kd. A representative result from 3 experiments is shown.
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the majority of the B burgdorferi–induced GAG release
is mediated by aggrecanases rather than by MMPs.
DISCUSSION
MMPs and ADAMTS are both members of the
broader family of metalloproteinases, the predominant
host enzymes that cleave extracellular matrix proteins
(11,33). Our understanding of the roles of each family
member in different diseases is continuing to evolve.
The expression of specific MMPs, including MMP-1,
MMP-3, MMP-13, and MMP-19, is induced in joint
tissue by infection with B burgdorferi (3,4,18). We show
herein that B burgdorferi is capable of inducing
ADAMTS-4, but not ADAMTS-5, in human chondro-
cytes.
The signaling pathways involved in the induction
of ADAMTS-4 by B burgdorferi show some overlap with
those responsible for the induction of MMPs, but nota-
bly, the p38 MAPK pathway does not seem to be
involved. Previous studies have shown that activation of
p38 MAPK is important both for the induction of MMPs
and for the development of joint swelling in infected
mice (19,34). This suggests that the pathways involved in
the induction of ADAMTS-4, and by extension, aggre-
can digestion and release, may be distinct from those
involved in the mediation of inflammation and swelling,
although they are likely to coexist in natural disease
states. Our studies of inbred strains of mice with differ-
ent susceptibilities to the development of Lyme arthritis
appear to confirm this. While the most susceptible
strain, C3H, exhibited a significant increase in
ADAMTS-4 in infected joint tissue, the 2 more resistant
strains, BALB/c and C57BL/6, were similar in their
ADAMTS-4 responses (no significant increase) despite
differences in joint swelling between the strains. Of note,
in arthritic diseases such as RA, joint swelling and
histologic progression of arthritis (e.g., permanent car-
tilage erosions) may be mediated by independent path-
ways; the effects of p38 inhibition on the development of
histologic evidence of arthritis in B burgdorferi–infected
mice has not been reported.
To determine whether ADAMTS-4 expression is
elevated in Lyme arthritis in humans, we compared
expression levels in SF samples from patients with
untreated Lyme arthritis, persistent Lyme arthritis after
antibiotic therapy, RA, OA, gouty arthritis, and ReA.
The cause of persistent Lyme arthritis after antibiotic
therapy remains a subject of controversy. Four basic
hypotheses have been proposed as a mechanism for
persistent Lyme arthritis after antibiotic therapy (35):
persistent infection, retained spirochetal antigens,
infection-induced autoimmunity resulting from molecu-
lar mimicry, and nonspecific bystander activation. For
the purposes of our study, the salient feature is that
patients with persistent Lyme arthritis after antibiotic
therapy have clearly lower amounts (if any) of bacteria
present in the joints and SF.
We found that SF levels of ADAMTS-4 were
significantly higher in patients with untreated Lyme
arthritis as compared with patients with persistent Lyme
arthritis after antibiotic therapy, which is consistent with
our in vitro studies showing that B burgdorferi directly
induces ADAMTS-4 production. Levels of expression of
the active form of ADAMTS-4 (p53) were similar in SF
from patients with untreated Lyme arthritis, RA, and
OA. These levels were significantly higher than those in
SF from patients with persistent Lyme arthritis after
antibiotic therapy and patients with gouty arthritis. As
with other inflammatory molecules, it is likely that
ADAMTS-4 can be induced by different stimuli that
result in similar activation of signaling pathways and the
release of cytokines (either from chondrocytes or from
migratory inflammatory cells). It is tempting to specu-
late that clinical progression and histologic changes are
governed by the specific set of proteases that are in-
duced and that similarities in histologic features of
disease (e.g., Lyme arthritis and RA) are due to similar-
ities in protease activity.
The catabolism of aggrecan with the subsequent
loss of GAG-bearing aggrecan fragments from articular
cartilage and their release into the SF is an early and
persistent process during arthritic diseases. We have
shown that GAG release in response to B burgdorferi in
a bovine explant model appears to be predominantly
mediated by aggrecanase activity and not by MMP
activity. Whether this remains true in vivo, where there
are many different factors, including the presence of
activators and inhibitors generated from other cells, has
not been ascertained. However, aggrecanase-type diges-
tion fragments of aggrecan have previously been re-
ported to be present in the joints of patients with Lyme
arthritis (3), confirming that at a minimum, aggre-
canases are active in Lyme arthritis.
Even if ADAMTS-4 plays the major role in
cleaving aggrecan in Lyme arthritis, this does not pre-
clude a role of MMPs in the development of arthritis.
Cleavage of aggrecan attached to the collagen matrix is
typically an early and fully reversible event in the
development of arthritis. Irreversible damage to the
cartilage matrix does not occur until collagen is cleaved
and degraded. Aggrecan has been shown to protect
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cartilage collagen from proteolytic cleavage (36). The
keratan sulfate–rich region of aggrecan binds to type II
collagen (37), thereby positioning the collagen fibril
where it is protected by the highly sulfated chondroitin
sulfate–rich regions of the aggrecan, preventing access
to the fibrils (36). Thus, in the development of arthritis,
cleavage and release of GAGs is a required early event
that subsequently allows access of collagenases such as
MMP-1 and MMP-13 to the collagen matrix. In Lyme
arthritis in humans, both ADAMTS-4 and collagenases
(MMP-1 and MMP-13) may be required for permanent
damage to occur. In support of this, mice, including the
most arthritis-susceptible C3H strains, do not have in-
creased levels of interstitial collagenases in response to
B burgdorferi infection and, in contrast to humans in-
fected with B burgdorferi, do not develop permanent
erosions, despite induction of ADAMTS-4 and noncolla-
genase MMPs such as MMP-3 and MMP-19 (18).
In conclusion, we have shown that B burgdorferi
induces the expression of ADAMTS-4 in human chon-
drocytes, in susceptible strains of mice, and in patients
with Lyme arthritis. Both in vitro and in vivo studies
have shown that this protease is processed and found in
its most active form—suggesting that it is likely having
an effect—within the joint. Our current model for the
pathogenesis of Lyme arthritis is that ADAMTS-4
cleaves aggrecan, thereby exposing the collagen matrix,
which can then be processed by MMPs, leading to
permanent cartilage degradation. Use of selective aggre-
canase inhibitors may impart cartilage protection by
preventing aggrecan degradation without some of the
negative responses associated with more broad-
spectrum MMP inhibitors. This will need to be deter-
mined by future studies.
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